Thursday, March 24, 2022 Daily Archives

WuXi Bio grabs larger piece of the bio CDMO pie

by

With over 10% of the biologics outsourcing market share, WuXi Biologics is now the second largest CDMO according to an analyst.  The China-based contract development manufacturing organization (CDMO) reported its end of year results for 2021. Revenues increased by 83.3% year-on-year to $1.6 billion and net profits grew by 107%, totaling $550 million. Furthermore, according to Chris Liu, an equity analyst at Jefferies, Wuxi is now the second largest player in the global biologics outsourcing market with 10.3% shares of…

March 24, 2022

Shape Therapeutics: ‘We’ve engineered a new kind of RNA’

by

Shape Therapeutics says its research on RNA editing technology could make it easier to repair disease-causing mutations without compromising efficiency. Prashant Mali, the co-founder of Shape, and his colleagues claim they have engineered a “new kind of guide RNA†that can recruit the cell’s own ADARs (an enzyme naturally found in the human body) to carry out edits at a precise target RNA region. According to Shape, ADARs have the ability to alter the RNA code and correct G-to-A mutations,…

March 24, 2022